These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Urinary excretion of porphyrins and their precursors. Longterm observations in acute intermittent porphyrias (author's transl)]. Brugsch J; Müller H MMW Munch Med Wochenschr; 1979 Mar; 121(13):457-8. PubMed ID: 107424 [TBL] [Abstract][Full Text] [Related]
6. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943 [TBL] [Abstract][Full Text] [Related]
7. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Sardh E; Andersson DE; Henrichson A; Harper P Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004 [TBL] [Abstract][Full Text] [Related]
8. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry. Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490 [TBL] [Abstract][Full Text] [Related]
9. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Kauppinen R; von und zu Fraunberg M Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973 [TBL] [Abstract][Full Text] [Related]
10. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Aarsand AK; Petersen PH; Sandberg S Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824 [TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Sardh E; Rejkjaer L; Andersson DE; Harper P Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984 [TBL] [Abstract][Full Text] [Related]
12. Excretion of porphyrins and porphyrin precursors during neuromuscular paralysis produced by dithiobiuret. Atchison WD; Peterson RE Exp Neurol; 1984 Jul; 85(1):63-8. PubMed ID: 6428932 [TBL] [Abstract][Full Text] [Related]
13. Elevated porphyrins following propofol anaesthesia in acute intermittent porphyria. Elcock D; Norris A Anaesthesia; 1994 Nov; 49(11):957-8. PubMed ID: 7802240 [TBL] [Abstract][Full Text] [Related]
14. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305 [TBL] [Abstract][Full Text] [Related]
15. Comparative effects of glycerol and dextrose on porphyrin precursor excretion in acute intermittent porphyria. Bonkowsky HL; Magnussen CR; Collins AR; Doherty JM; Hess RA; Tschudy DP Metabolism; 1976 Apr; 25(4):405-14. PubMed ID: 1263834 [TBL] [Abstract][Full Text] [Related]
16. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Gross U; Honcamp M; Daume E; Frank M; Düsterberg B; Doss MO Horm Metab Res; 1995 Aug; 27(8):379-83. PubMed ID: 7590628 [TBL] [Abstract][Full Text] [Related]